Abstract

Background. Epigenetic changes of TSG are supposed as the most fine and active genes regulation mechanism in particular breast cancer (BC) genes pathway development. The most valuable results are awaited for methylation role of genes located on the short arm of chromosome 3 with also MGMT gene (10q26) in BC pathogenesis because of their ambiguous data for methylation status in tumors. Objective: to illustrate the specific methylation role of the RASSF1A, SEMA3B, RARß2, RHOA, GPX1, USP4, DAG1, NKIRAS1 and MGMT genes promoter regions in BC pathogenesis. Materials and methods. Sample set of 174 BC patients consists of tumor and surrounding histologically normal tissue that were collected and clinically characterized in the N.N. Blokhin National Medical Research Center of Oncology. Two substantive methods were used to evaluate DNA methylation status. To analyse RASSF1A, SEMA3B, RARß2 and MGMT genes methylation we used polymerase chain reaction specific for the methylated allele. Whereas for analyses RHOA, GPX1, USP4, DAG1, NKIRAS1 promoter regions genes methylation status was used methyl sensitive restriction analyses with 2 methyl sensitive endonuclaeses HpaII and HhaI with subsequent polymerase chain reaction. Results. A statistically significant high frequency of RASSF1A, SEMA3B, RARß2, and MGMT genes methylation in epithelial breast tumors compared with histologically normal tissue from the same patients was shown. Significant correlation of RARß2 and MGMT genes methylation frequency considering the different clinical and morphological characteristics of the malignant process was revealed. The statistically significant relationship between methylation of RASSF1A, RARß2 and MGMT genes and patient survival is shown for the first time. Conclusion. The findings of epigenetic changes in the luminal BC supplement the “molecular picture” of this cancer and contribute to an understanding of its pathogenesis. The revealed features of investigated genes methylation can find clinical application for the development of modern approaches to prognosis, prevention and choice of tactics for treatment of BC in females of the Moscow region.

Highlights

  • The most valuable results are awaited for methylation role of genes located on the short arm of chromosome 3 with MGMT gene (10q26) in breast cancer (BC) pathogenesis because of their ambiguous data for methylation status in tumors

  • Whereas for analyses RHOA, glutathione peroxidase 1 (GPX1), USP4, DAG1, NKIRAS1 promoter regions genes methylation status was used methyl sensitive restriction analyses with 2 methyl sensitive endonuclaeses HpaII and HhaI with subsequent polymerase chain reaction

  • A statistically significant high frequency of RASSF1A, SEMA3B, RARβ2, and MGMT genes methylation in epithelial breast tumors compared with histologically normal tissue from the same patients was shown

Read more

Summary

Оригинальные статьи

Цель исследования – изучение роли метилирования промоторных районов генов RASSF1A, SEMA3B, RARβ2, RHOA, GPX1, USP4, DAG1, NKIRAS1 и MGMT в патогенезе эпителиальных опухолей молочной железы. Метилирование генов RASSF1A, SEMA3B, RARβ2 и MGMT изучали с помощью полимеразной цепной реакции, специфичной к метилированному аллелю. Анализ метилирования промоторных районов генов RHOA, GPX1, USP4, DAG1 и NKIRAS1 выполняли с применением 2 метилчувствительных рестриктаз – HpaII и HhaI – и последующей полимеразной цепной реакции. Показана статистически значимо высокая частота метилирования генов RASSF1A, SEMA3B, RARβ2 и MGMT в эпителиальных опухолях молочной железы по сравнению с гистологически нормальной тканью от тех же пациенток. Впервые показана статистически значимая связь между метилированием генов RASSF1A, RARβ2 и MGMT и выживаемостью пациенток. Выявленные особенности метилирования исследованных генов могут найти клиническое применение для разработки современных подходов к прогнозированию, профилактике и выбору тактики лечения РМЖ у пациенток московского региона. Blokhin National Medical Research Center of Oncology; 24 Kashirskoe Sh., Moscow 115478, Russia; 2Institute of General Pathology and Pathophysiology; 8 Baltiyskaya St., Moscow 125315, Russia; 3Research Center of Medical Genetics; 1 Moskvorech’e St., Moscow 115478, Russia

Background
Materials and methods
Фактор n
Нормальная ткань n
Подтип А Ген n
Нет метилирования
Findings
Умерли Живы Нет метилирования Есть метилирование
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call